Table 3 Subgroup analysis of changes in AHREs burden after dapagliflozin vs. placebo among CIED patients with clinical AF.

From: Effects of sodium-glucose cotransporter-2 inhibitor on atrial high-rate episodes in patients with cardiovascular implantable electronic device: a randomized controlled trial

AHREs Burden

Dapagliflozin

N = 17

Placebo

N = 15

P value

Δ duration (min)

%Δ duration

− 85.0, − 870.0 to 258.8

− 23.3, − 67.4 to 18.8

− 189.5, − 335.2 to (− 6.8)

− 44.6, − 84.8 to (− 19.9)

0.739

0.298

Δ total burden (percent)

%Δ total burden

0.5, − 0.2 to 7.2

2.3, − 30.7 to 106.2

1.6, − 1.0 to 3.6

29.0, − 58.3 to 94.1

0.545

0.890

Δ no. of episodes (times/mo)

%Δ no. of episodes

− 2.2, − 31.2 to 1.0

− 34.7, − 76.2 to 36.1

0.6, − 0.8 to 5.9

25.0, − 14.5 to 66.8

0.048*

0.160

  1. Data are shown as median, IQR unless specified.
  2. Δ = AHREs3mo-AHREsbaseline. (−) Negative value means AHREs burden has decreased from baseline.
  3. *p value < 0.05.
Back to article page